Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
91.28M | 17.16M | 10.29M | 63.17M | 75.00M | Gross Profit |
91.28M | 14.78M | 7.95M | -35.32M | -5.03M | EBIT |
-114.95M | -164.41M | -115.15M | -56.81M | -23.88M | EBITDA |
-92.74M | -143.16M | -105.26M | -55.71M | -19.37M | Net Income Common Stockholders |
-145.23M | -163.62M | -128.72M | -57.19M | -19.92M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
385.37M | 390.90M | 441.24M | 548.10M | 393.65M | Total Assets |
483.83M | 452.39M | 610.38M | 643.07M | 416.55M | Total Debt |
16.04M | 17.81M | 19.45M | 20.95M | 342.00K | Net Debt |
-107.04M | -18.15M | -51.86M | -474.77M | -250.11M | Total Liabilities |
412.97M | 364.29M | 348.28M | 286.64M | 19.82M | Stockholders Equity |
70.87M | 88.10M | 262.10M | 356.43M | 396.73M |
Cash Flow | Free Cash Flow | |||
-135.69M | -121.61M | -73.95M | -47.29M | -14.73M | Operating Cash Flow |
-135.34M | -120.80M | -73.59M | -45.92M | -14.16M | Investing Cash Flow |
95.40M | 144.75M | -394.85M | 38.84M | 94.47M | Financing Cash Flow |
127.05M | -59.30M | 44.02M | 252.30M | -879.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | $719.85M | ― | -6.33% | ― | 23.92% | -27.69% | |
55 Neutral | $639.97M | ― | -55.12% | ― | ― | -60.26% | |
53 Neutral | $5.14B | 3.23 | -45.01% | 2.85% | 17.55% | -0.69% | |
49 Neutral | $621.12M | 53.85 | -4.52% | ― | 92.31% | 78.17% | |
46 Neutral | $600.54M | ― | -343.83% | ― | 387.20% | 21.00% | |
46 Neutral | $490.86M | ― | -75.77% | ― | ― | -44.25% | |
45 Neutral | $529.54M | ― | -43.77% | ― | 20.38% | -194.93% |
On February 12, 2025, AnaptysBio announced significant results from its Phase 2b RENOIR trial for rosnilimab in treating moderate-to-severe rheumatoid arthritis. The trial demonstrated efficacy in key endpoints, including a significant reduction in DAS-28 CRP scores and high CDAI LDA responses, with favorable safety and tolerability profiles, marking a promising advancement in RA treatment.